Advocacy Action &...
Follow
Find
1.5K views | +0 today
Rescooped by Heather Swift from Breast Cancer News
onto Advocacy Action & Issues in Cancer
Scoop.it!

Supreme Court decision to affect breast cancer testing

Supreme Court decision to affect breast cancer testing | Advocacy Action & Issues in Cancer | Scoop.it

"The U.S. Supreme Court is expected to announce a decision as early as Thursday that will affect the affordability of a key genetic test for breast cancer susceptibility.

The decision, in a lawsuit over a Utah-based company's patents on genetic material, is expected just as a new study suggests that the inherited mutations the test identifies are common in African-American women, an often understudied population that is disproportionately affected by breast cancer.

And the decision could well affect black women in the Milwaukee area, where officials at Froedtert & The Medical College of Wisconsin are producing a documentary that aims to increase awareness about breast cancer risk and treatment among low-income or underinsured African-American women."


Via Susan Zager
Heather Swift's insight:

The article points out that there are financial barriers because of the test - it can cost over $3000 - and given that African-American women are more likely to carry a gene mutation, it's difficult to get the data for this because Myriad holds all of the data as well as the patent on the genetic BRCA1 abd BRCA2 mutations for breast and ovarian cancer.

more...
Susan Zager's curator insight, June 13, 2013 7:09 AM

The article points out that there are financial barriers because of the test - it can cost over $3000 - and given that African-American women are more likely to carry a gene mutation, it's difficult to get the data for this because Myriad holds all of the data as well as the patent on the genetic BRCA1 abd BRCA2 mutations for breast and ovarian cancer.


Advocacy Action & Issues in Cancer
Awareness is nothing without Action... Here's what's happening now and how YOU can create change!
Curated by Heather Swift
Your new post is loading...
Your new post is loading...
Rescooped by Heather Swift from Breast Cancer News
Scoop.it!

Demand Insurance Coverage for Breast Cancer Genetic Marker Testing

Demand Insurance Coverage for Breast Cancer Genetic Marker Testing | Advocacy Action & Issues in Cancer | Scoop.it

Tell Secretary Sebelius to adopt a legislation requiring insurance companies to provide coverage for BRCA gene mutation testing. 

Mutation of the BRCA1 and BRCA2 genes have been linked to the development of hereditary breast and ovarian cancer. According to the National Cancer Institute, about 12% of women in the general population will develop breast cancer sometime during their lives, compared with about 60% of women who have inherited a harmful mutation in BRCA1 or BRCA2 genes. Genetic testing can reveal an inherited BRCA1 or BRCA2 mutation.

Although insurance companies often cover genetic testing, coverage is not guaranteed. Take action today - urge Secretary of the Department of Health and Human Services Kathleen Sebelius to adopt legislation requiring insurance companies to cover genetic counseling and testing for the BRAC1 and BRAC2 mutations upon medical recommendation."


Via Susan Zager
Heather Swift's insight:
Susan Zager's insight: All women who have a risk of carrying a BRCA gene mutation have a right to testing covered by insurance. SIGN today-IT's easy and pre-written.
more...
Susan Zager's curator insight, July 7, 10:36 AM

All women who have a risk of carrying a BRCA gene mutation have a right to testing covered by insurance. SIGN today-IT's easy and pre-written. 

Scooped by Heather Swift
Scoop.it!

Dear Andrea Mitchell: Early Detection is Not a Breast Cancer Cure

Dear Andrea Mitchell: Early Detection is Not a Breast Cancer Cure | Advocacy Action & Issues in Cancer | Scoop.it
Yesterday, MSNBC's Andrea Mitchell announced she was diagnosed with breast cancer. “I had planned to be hiking in Wyoming last week, but instead discovered that I am now among the one in eight wome...
more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

VEGF Inhibitors Trigger Hypertension, Possible Cardiovascular Events - Chemotherapy Advisor

VEGF Inhibitors Trigger Hypertension, Possible Cardiovascular Events - Chemotherapy Advisor | Advocacy Action & Issues in Cancer | Scoop.it
Antiangiogenic cancer therapies elevate blood pressure in almost all patients, and put some at risk for stroke and myocardial infarction.
Heather Swift's insight:

Antiangiogenic cancer therapies elevate blood pressure in almost all patients, and put some at risk for stroke and myocardial infarction.

more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

Lilly Loses Patent Dispute With Actavis Over Cancer Treatment

Lilly Loses Patent Dispute With Actavis Over Cancer Treatment | Advocacy Action & Issues in Cancer | Scoop.it
Eli Lilly & Co. lost a U.K. lawsuit over its Alimta cancer treatment when a judge ruled that a generic version planned by Actavis Plc doesn’t breach European patents.
more...
No comment yet.
Rescooped by Heather Swift from Breast Cancer News
Scoop.it!

NBCC's Upcoming Clinical Trials for Women with Metastatic Breast Cancer

NBCC's Upcoming Clinical Trials for Women with Metastatic Breast Cancer | Advocacy Action & Issues in Cancer | Scoop.it

"NBCC is currently partnering with BioMarin and Pfizer on three upcoming clinical trials for women with metastatic breast cancer. Intervention offers the potential of improving the length and quality of life for patients already diagnosed with metastatic breast cancer. Trial accrual has begun for all three studies.

NBCC advocates have been involved in many ways on these trials in the development of the protocols, as members of the Date Safety Monitoring Board, as reviewers of educational materials and consent forms and in conducting outreach activities to educate the public about the trials.


Via Susan Zager
more...
Susan Zager's curator insight, February 19, 1:09 PM


Here are the trials that the NBCC is partnering with Biomarin and Pfizer for Metastatic Breast Cancer:


EMBRACA clinical trial for the PARP inhibitor BMN 673 (BioMarin)

  • Purpose of the study:   To evaluate the efficacy and safety of BMN 673 in the metastatic setting.
  • Eligibility:  Women with the BRCA1 or BRCA 2 mutation and locally advanced or metastatic breast cancer.  Other eligibility criteria and trial details can be found at  http://clinicaltrials.gov/ct2/show/NCT01945775.
PALOMA 2 clinical trial for the CDK 4/6 inhibitor Palbociclib (Pfizer).
  • Purpose of study:  To evaluate the efficacy and safety of Palbociclib with letrozole in the metastatic setting.
  • Eligibility: First-line treatment of postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer.  Other eligibility criteria and trial details can be found at http://clinicaltrials.gov/show/NCT01740427


PALOMA 3 clinical trial for CDK 4/6 inhibitor Palbociclib (Pfizer).

  • Purpose of study: To evaluate the efficacy and safety of Palbociclib with fulvestrant in the metastatic setting.
  • Eligibility: Women with HR+/HER2- locally advanced or metastatic breast cancer who progressed on or after prior endocrine therapy. Other eligibility criteria and trial details can be found at  http://clinicaltrials.gov/show/NCT01942135 .
For more information contact the NBCC at: clinicaltrials@breastcancerdeadline2020.org
Maria Fowler's curator insight, February 22, 8:27 AM

The BMN 673 trial is for a PARP inhibitor which may eventually help with metaplastic breast cancer.

Scooped by Heather Swift
Scoop.it!

NIH to Researchers: Credibility Counts

NIH to Researchers: Credibility Counts | Advocacy Action & Issues in Cancer | Scoop.it
The NIH is planning significant interventions” to ensure that basic biomedical studies stand the test of time, its two top officials say.
more...
No comment yet.
Rescooped by Heather Swift from Patient Information
Scoop.it!

Why I tweet: A patient advocate view

Why I tweet: A patient advocate view | Advocacy Action & Issues in Cancer | Scoop.it

Twitter — its functions, benefits, risks and limitations — has figured prominently in the heated discussion about Emma and Bill Keller’s respective editorials in The Guardian (since deleted, though the archived version is still available) and the New York Times about the Twitter feed of Lisa Bonchek Adams. I have followed Lisa for a long time and greatly admire her thoughtful, highly personal tweets about the ups and downs of what it takes for her to face the challenges of metastatic breast cancer. Her generosity of spirit is a gift to many of us.

 

In comparison, I am a different type of tweeter, posting a weekday stream of tweets aimed at addressing generally the subject that Lisa talks about so personally: finding and making the best possible use of health care. This is a description of what I tweet — and why.

 

Since 1992, I have advocated for all of us to have the information, support and guidance we need to act to improve our health and get the most from our health care. I believe — and there is evidence to back me up — that we do better when we participate in our care to the extent we are able with as much knowledge about what might work that we can absorb.

 

Read more: http://www.kevinmd.com/blog/2014/02/tweet-patient-advocate-view.html


Via Parag Vora
more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

Pancreatic Cancer Action Campaign: I Wish I Had Breast Cancer

Pancreatic Cancer Action Campaign: I Wish I Had Breast Cancer | Advocacy Action & Issues in Cancer | Scoop.it
Congratulations, Pancreatic Cancer Action. Your brilliant marketing plan is working. It was a stroke of genius to have Tube ads and YouTube videos of people saying "I wish I had testicular cancer" ...
Heather Swift's insight:

[MIND BOGGLING] 

 

more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

Breast Cancer Action Annual Report

Heather Swift's insight:

[BREAST CANCER ACTION]
Together we continue to build a powerful, grassroots movement to address and end the breast cancer epidemic and achieve historic wins for women everywhere. We’re so proud to share with you the successes of the 2012-2013 fiscal year:

    After five years of opposing corporate monopolies on our genes, we won a landmark victory when the U.S. Supreme Court ruled in our favor to outlaw patents on the “breast cancer genes.”
    We took a leadership role in the movement to end hydraulic fracturing (“fracking”), a toxic process of energy extraction that inherently threatens public health.
    We distributed over 10,000 Think Before You Pink® Toolkits to grassroots activists across the U.S., empowering them to take action to stop pinkwashing.
    Through our Community Leaders for Change program (formerly the Speakers Bureau), we mobilized and trained 23 community-based activists across the country.
    Our free webinar series attracted nearly 2,000 participants nationally with information about screening and detection, media literacy, pinkwashing, toxic cosmetics, and more.

These are just highlights; please, download the full annual report from fiscal year 2012-2013.

more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

Social Media & Cancer Drugs: Conversation, not Promotion | Xconomy

Social Media & Cancer Drugs: Conversation, not Promotion | Xconomy | Advocacy Action & Issues in Cancer | Scoop.it
Social media hasn’t yet changed the world for biotech and pharma companies, but I believe this year is the year that will change. For better or worse, thes
more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

ACS CAN Response to the 2014 State of the Union Address

ACS CAN Response to the 2014 State of the Union Address | Advocacy Action & Issues in Cancer | Scoop.it
I heard it. Did you? President Obama mentioned cancer during last nights' State of the Union Address? I just watched this short video from the American Cancer Society Cancer Action Network that lays out the impact his speech will have on fighting #cancer in 2014. http://bit.ly/1exH3cf
Heather Swift's insight:

Last night, the President delivered the State of the Union Address outlining his priorities for the year.

In the speech, he mentioned several issues that are very important in the fight against cancer.

Dick Woodruff, ACS CAN's vice president of federal relations, taped a video response this morning to tell you more about what the President said and what lies ahead in our work to make fighting cancer a national priority.

more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

A health journalist with breast cancer finds herself caught between statistics and personal decisions - The Boston Globe

A health journalist with breast cancer finds herself caught between statistics and personal decisions - The Boston Globe | Advocacy Action & Issues in Cancer | Scoop.it
One afternoon last fall, I was pacing the high school parking lot, straining to see my son running in his first cross-country meet, while absently absently listening to Muzak on my cell phone.
more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

A Perfect Storm In The DCIS Sea of Uncertainty: Kellergate

A Perfect Storm In The DCIS Sea of Uncertainty: Kellergate | Advocacy Action & Issues in Cancer | Scoop.it
No power so effectually robs the mind of all its powers of acting and reasoning as fear. For fear being an apprehension of pain or death, it operates in a manner that resembles actual pain." - Edmu...
more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

Why do we think more care is better for us?

Why do we think more care is better for us? | Advocacy Action & Issues in Cancer | Scoop.it
If we want to improve the health of our nation, we need to reduce the cost of medical treatment and stop wasting money on care that adds no value.
more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

Lilly Loses Patent Dispute With Actavis Over Cancer Treatment

Eli Lilly & Co. lost a U.K. lawsuit over its Alimta cancer treatment when a judge ruled that a generic version planned by Actavis Plc doesn’t breach European patents.
Heather Swift's insight:
Court Rules Against Lilly In Cancer Treatment Patent Dispute With Actavis.

Bloomberg News (5/15, Chellel) reported that a UK court ruled against Eli Lilly & Co. in a patent case, noting that “a generic version planned by Actavis Plc” doesn’t “breach European patents” of the company’s Alimta (Pemetrexed) cancer treatment. Lilly, which reported first-quarter sales of $632 million from Alimta in 2014, “has fought lawsuits across the globe to protect patents related to the product.” The article noted that in March, a US District Court “upheld a patent regarding vitamin dosage in a dispute with Teva Pharmaceutical Industries Ltd.”

        Reuters (5/16) reported on Actavis’ plans to market the medicine, noting that if it wins any appeal, it expects to begin selling it once the patent on Alimta comes to an end in December 2015

more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

New study finds 102 common chemicals linked to breast cancer

New study finds 102 common chemicals linked to breast cancer | Advocacy Action & Issues in Cancer | Scoop.it
New study finds 102 common chemicals linked to breast cancer | A national effort to protect families from toxic chemicals.
Heather Swift's insight:
[CHEMICALS & CANCER] Last week, the Silent Spring Institute published a study that found 102 chemicals linked to breast cancer. What is most alarming, is the fact that these are chemicals we're exposed to every single day.
more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

What medical device technology could improve cancer detection in dense breasts?

What medical device technology could improve cancer detection in dense breasts? | Advocacy Action & Issues in Cancer | Scoop.it
Medical device technology companies offer ways to improve breast cancer detection for women with dense breasts.
Heather Swift's insight:
As dense breast legislation increases, how can medical device technology improve breast cancer detection?

About 14 states have a law that requires radiologists to notify women if they’re found to have dense breasts.

more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

What Should Oncology Nurses Know About Type I and Type II Errors in a Clinical Study? | ons connect

What Should Oncology Nurses Know About Type I and Type II Errors in a Clinical Study? | ons connect | Advocacy Action & Issues in Cancer | Scoop.it
more...
No comment yet.
Rescooped by Heather Swift from Breast Cancer News
Scoop.it!

National Breast Cancer Coalition Awards Additional Seed Grant for Preventive Breast Cancer Vaccine: Breast Cancer Deadline 2020

National Breast Cancer Coalition Awards Additional Seed Grant for Preventive Breast Cancer Vaccine: Breast Cancer Deadline 2020 | Advocacy Action & Issues in Cancer | Scoop.it

"Washington, DC, February 6, 2013—Through the generous support of National Philanthropic Trust (NPT), the National Breast Cancer Coalition (NBCC) announced today that it has awarded a seed grant to Dr. Paul Ewald, Professor of Biology and Director, Program on Disease Evolution at the University of Louisville, and Dr. Vladimir Belyi, Assistant Professor at the Cancer Institute of New Jersey, Robert Wood Johnson Medical School. The researchers will take a systematic look through two sets of breast cancer genomes for evidence of infectious agents. Bioinformatic tools will be used to compare the presence of infectious agents in breast tumors with normal breast tissue. Researchers will then look at the biological mechanisms of the infectious agents to understand the relationships between these agents and breast cancer.

This seed grant is part of NBCC’s Artemis Project® for a preventive vaccine, which brings together a collaborative group of advocates and scientists to take a strategic, systematic yet broad approach to the development of a breast cancer vaccine within five years.

An earlier seed grant was awarded to  Dr. Paul Spellman and Dr. Joe Gray of Oregon Health and Science University to identify possible vaccine targets using existing and developing human genomic data within different breast cancer subtypes. The analysis will generate a prioritized list of about 50-100 potential breast cancer specific targets to be considered for incorporation into a preventive vaccine. Initial data from research for both seed grants will be presented at the Artemis Project® annual meeting to be held next month.

"I am grateful to NBCC and NPT for making available, through the Artemis Project®, a platform to explore the relationships between infectious agents and breast cancer so we can gain the necessary insights that will lead us to developing a preventive vaccine from breast cancer," said Dr. Ewald."



Via Susan Zager
more...
Scooped by Heather Swift
Scoop.it!

'I wish I had breast cancer': Charity's slogan causes outrage

'I wish I had breast cancer': Charity's slogan causes outrage | Advocacy Action & Issues in Cancer | Scoop.it
The 'envy' campaign was devised by the charity Pancreatic Cancer Action to highlight the poor survival rates of the disease.
Heather Swift's insight:

[PCA CANCER-ENVY ADS]
'I wish I had breast cancer': Pancreatic cancer charity's campaign slogan causes outrage with other sufferers of the disease

The 'envy' campaign was devised by the charity Pancreatic Cancer Action to highlight the poor survival rates of the disease compared to other types of cancer such as breast and prostate
But critics have condemned it, calling it 'horribly insensitive' and 'repugnant'

more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

Cummings Applauds SSA’s Inclusion of Stage IV Prostate Cancer in CAL Conditions | ons connect

Cummings Applauds SSA’s Inclusion of Stage IV Prostate Cancer in CAL Conditions | ons connect | Advocacy Action & Issues in Cancer | Scoop.it
more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

CureToday.com: Blogs - Guest - Federal funding for cancer research: The good, the bad and the ugly

CureToday.com: Blogs - Guest - Federal funding for cancer research: The good, the bad and the ugly | Advocacy Action & Issues in Cancer | Scoop.it
Heather Swift's insight:

Federal Funding for Cancer Research: The Good, the Bad and the Ugly
After a tumultuous year of debates and shutdowns, Congress has passed legislation that will fund cancer research and education—but does the bill do enough? Calaneet Balas of the Ovarian Cancer National Alliance explains what it may mean for gynecological cancers.

more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

HOT TOPICS 2014: Health Policy
(Post Date: 1/28/14)

HOT TOPICS 2014: Health Policy<br/>(Post Date: 1/28/14) | Advocacy Action & Issues in Cancer | Scoop.it
Heather Swift's insight:

What will be the most important issues to watch in health policy in 2014? Three experts in the field share their views. They focused on continuing enrollment and implementation of the Affordable Care Act and trends in healthcare spending.

more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

Advocating For Oral Parity in Missouri: The Leu... | The Leukemia & Lymphoma Society Community

Advocating For Oral Parity in Missouri: The Leu... | The Leukemia & Lymphoma Society Community | Advocacy Action & Issues in Cancer | Scoop.it
more...
No comment yet.
Scooped by Heather Swift
Scoop.it!

Funding Cancer Research: The Danger of Brightly Colored Ribbons

Funding Cancer Research: The Danger of Brightly Colored Ribbons | Advocacy Action & Issues in Cancer | Scoop.it
Pink ribbons are for breast cancer, dark blue ribbons are for colon cancer, and so on.
more...
No comment yet.